NCT03415984

Prevalence of Age Related Macular Degeneration (ARMD) in Parkinson's Patients and Assesment of the Role of L-DOPA

Evaluation of the Prevalence of Age Related Macular Degeneration (ARMD) in Parkinson's Patients and Assesment of the Role of L-DOPA (AMD-PARK)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 133 (actual)
• Sponsor: Fondation Ophtalmologique Adolphe de Rothschild · Network
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

Age related macular degeneration (ARMD) is a major and irreversible cause of blindness among the elderly. The sub-retinal space, located between the retinal pigmentary epithelium (RPE) and the external segments of the retinal photoreceptors, plays a crucial role in this pathology. A recent epidemiologic study in the US, has shown that Parkinson patients treated with L-DOPA, developed only later an ARMD when compared to the untreated patients. The L-Dopa is an endogenous ligand of the GPR43 receptor (G protein-coupled receptors), located on the RPE's cell's apical pole. This receptor, via several intracellular mechanisms, regulates the cell's exosomal and endosomal pathways: it would appear that the L-DOPA, by stimulating this receptor, decreases significantly the RPE's exosome release. The contents of the exosomes is still uncertain, however in addition to their signalization role, it seems they transport pro-inflammatory components, possibly helping the cellular recruitment due to the mononuclear phagocytic systems, particularly toxic for the photoreceptors. The aim of this study is to estimate the prevalence of ARMD in a sample of Parkinson's Patients followed at Fondation Ophtalmologique Adolphe de Rothschild and to compared it to the prevalence of ARMD of the general population. Furthermore the study aims to explore a possible causal link between L-DOPA treatment and ARMD.

Conditions

• Parkinson Disease
• Age Related Macular Degeneration

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Color retinography	Color retinography
DIAGNOSTIC_TEST	Optical coherence tomography	Optical coherence tomography
DIAGNOSTIC_TEST	Fundus autofluorescence imaging	Fundus autofluorescence imaging

Timeline

• Start date: 2018-01-19
• Primary completion: 2019-01-15
• Completion: 2019-01-15
• First posted: 2018-01-30
• Last updated: 2019-02-01

Locations

1 site across 1 country: France